Product Comparison


 
Sanofi Pasteur 49281042150
Seqirus USA Inc 70461042110
Seqirus USA Inc 70461032103
Seqirus USA Inc 33332042110
Seqirus USA Inc 33332032101
McKesson # 1182062 1183068 1183069 1183078 1183075
Description Fluzone® Quadrivalent 2021 - 2022 Flu Vaccine 60 mcg / 0.5 mL Indicated For People 6 Months of Age and Above Prefilled Syringe 0.5 mL Flucelvax® Quadrivalent 2021 - 2022 Flu Vaccine 60 mcg / 0.5 mL Indicated For People 2 Years of Age and Above Multiple Dose Vial 5 mL Flucelvax® Quadrivalent 2021 - 2022 Flu Vaccine 60 mcg / 0.5 mL Indicated For People 2 Years of Age and Above Prefilled Syringe 0.5 mL Afluria® Quadrivalent 2021 - 2022 Flu Vaccine 60 mcg / 0.5 mL Indicated for People 6 Months of Age and Above Multiple Dose Vial 5 mL Afluria® Quadrivalent 2021 - 2022 Flu Vaccine 60 mcg / 0.5 mL Indicated For People 3 Years of Age and Above Prefilled Syringe 0.5 mL
Manufacturer # 4928104215070461042110704610321033333204211033332032101
Brand Fluzone® Quadrivalent 2021 - 2022Flucelvax® Quadrivalent 2021 - 2022Flucelvax® Quadrivalent 2021 - 2022Afluria® Quadrivalent 2021 - 2022Afluria® Quadrivalent 2021 - 2022
Manufacturer Sanofi PasteurSeqirus USA IncSeqirus USA IncSeqirus USA IncSeqirus USA Inc
Invoice FLUZONE 2021 QUAD, SYR 0.5ML (10 DOSE/BX)FLUCELVAX 2021, QUAD MDV 5ML (10DOSE/VL)FLUCELVAX 2021, QUAD SYR 0.5ML(10DOSE/BX)AFLURIA 2021, QUAD MDV 5ML (10DOSE/VL)AFLURIA 2021, QUAD SYR 0.5ML (10DOSE/BX)
    Log In to Order   Log In to Order   Log In to Order   Log In to Order   Log In to Order

Comparison

Alternate Manufacturer Number 158651015864781586536
Container Type Prefilled SyringeMultiple Dose VialPrefilled SyringeMultiple Dose VialPrefilled Syringe
Country of Origin United StatesUnited StatesUnited StatesAustraliaAustralia
Generic Drug Code 495794958349814
NDC Number 49281-0421-5070461-0421-1070461-0321-0333332-0421-1033332-0321-01
Product Dating McKesson Acceptable Dating: we will ship >= 180 daysMcKesson Acceptable Dating: we will ship >= 90 daysMcKesson Acceptable Dating: we will ship >= 180 daysMcKesson Acceptable Dating: we will ship >= 180 daysMcKesson Acceptable Dating: we will ship >= 180 days
User Indicated For People 6 Months of Age and AboveIndicated For People 2 Years of Age and AboveIndicated For People 2 Years of Age and AboveIndicated For People 6 Months of Age and AboveIndicated For People 3 Years of Age and Above
Volume 0.5 mL5 mL0.5 mL5 mL0.5 mL
Application Flu VaccineFlu VaccineFlu VaccineFlu VaccineFlu Vaccine
Dosage Form InjectionInjectionInjectionInjectionInjection
Storage Requirements Requires RefrigerationRequires RefrigerationRequires RefrigerationRequires RefrigerationRequires Refrigeration
Strength 60 mcg / 0.5 mL60 mcg / 0.5 mL60 mcg / 0.5 mL60 mcg / 0.5 mL60 mcg / 0.5 mL
Type IntramuscularIntramuscularIntramuscularIntramuscularIntramuscular
UNSPSC Code 5120160851201608512016085120160851201608
Features and Benefits
  • Fluzone Quadrivalent is a vaccine indicated for active immunization for the prevention of influenza disease caused by influenza A subtype viruses and type B viruses contained in the vaccine
  • Fluzone Quadrivalent is indicated for active immunization in persons 6 Months of age and older
  • Fluzone Quadrivalent is standardized according to United States Public Health Service requirements and is formulated to contain HA of each of the following four influenza strains recommended for the 2021 - 2022 influenza season: A/Brisbane/02/2018 IVR-190 (H1N1), A/Kansas/14/2017 X-327 (H3N2), B/Phuket/3073/2013 (B Yamagata lineage), and B/Maryland/15/2016 BX-69A (a B/Colorado/6/2017-like virus, B Victoria lineage).
  • FLUCELVAX QUADRIVALENT is an inactivated vaccine indicated for active immunization for the prevention of influenza disease caused by influenza virus subtypes A and type B contained in the vaccine
  • FLUCELVAX is approved for use in persons 2 years of age and older
  • FLUCELVAX QUADRIVALENT 5 mL multi-dose vial formulation contains no antibiotics
  • FLUCELVAX QUADRIVALENT is standardized according to United States Public Health Service requirements for the 2021 - 2022 influenza season and is formulated to contain a total of 60 micrograms (mcg) hemagglutinin (HA) per 0.5 mL dose in the recommended ratio of 15 mcg HA of each of the following four influenza strains:
  • A/Idaho/07/2018 (an A/Brisbane/02/2018 (H1N1)pdm09-like virus), A/Indiana/08/2018 (an A/Kansas/14/2017 (H3N2)-like virus), B/Iowa/06/2017 (a B/Colorado/06/2017-like virus), B/Singapore/INFTT-16-0610/2016 (a B/Phuket/3073/2013-like virus)
  • FLUCELVAX QUADRIVALENT is an inactivated vaccine indicated for active immunization for the prevention of influenza disease caused by influenza virus subtypes A and type B contained in the vaccine
  • FLUCELVAX is approved for use in persons 2 years of age and older
  • FLUCELVAX QUADRIVALENT 0.5 mL pre-filled syringes contain no preservative or antibiotics
  • FLUCELVAX QUADRIVALENT is standardized according to United States Public Health Service requirements for the 2021 - 2022 influenza season and is formulated to contain a total of 60 micrograms (mcg) hemagglutinin (HA) per 0.5 mL dose in the recommended ratio of 15 mcg HA of each of the following four influenza strains:
  • A/Idaho/07/2018 (an A/Brisbane/02/2018 (H1N1)pdm09-like virus), A/Indiana/08/2018 (an A/Kansas/14/2017 (H3N2)-like virus), B/Iowa/06/2017 (a B/Colorado/06/2017-like virus), B/Singapore/INFTT-16-0610/2016 (a B/Phuket/3073/2013-like virus)
  • AFLURIA QUADRIVALENT is an inactivated influenza vaccine indicated for active immunization against influenza disease caused by influenza A subtype viruses and type B viruses contained in the vaccine
  • AFLURIA QUADRIVALENT is approved for use in persons 6 Months and older
  • The multi-dose presentation contains thimerosal added as a preservative; each 0.5 mL dose contains 24.5 mcg of mercury
  • AFLURIA QUADRIVALENT is standardized according to USPHS requirements for the 2021 - 2022 influenza season and is formulated to contain 60 mcg hemagglutinin (HA) per 0.5 mL dose in the recommended ratio of 15 mcg HA for each of the four influenza strains recommended for the 2020 - 2021 Northern Hemisphere influenza season:
  • A/Brisbane/02/2018 (IVR-190) (an A/Brisbane/02/2018 (H1N1)pdm09 – like virus), A/Kansas/14/2017 (X-327) (an A/Kansas/14/2017 (H3N2) – like virus), B/Maryland/15/2016 (a B/Colorado/06/2017 – like virus) and B/Phuket/3073/2013 BVR-1B (a B/Phuket/3073/2013 – like virus). A 0.25 mL dose contains 7.5 mcg HA of each of the same four influenza strains.
  • AFLURIA QUADRIVALENT is an inactivated influenza vaccine indicated for active immunization against influenza disease caused by influenza A subtype viruses and type B viruses contained in the vaccine
  • AFLURIA QUADRIVALENT is approved for use in persons 3 Years of age and older
  • AFLURIA QUADRIVALENT is standardized according to USPHS requirements for the 2021 - 2022 influenza season and is formulated to contain 60 mcg hemagglutinin (HA) per 0.5 mL dose in the recommended ratio of 15 mcg HA for each of the four influenza strains recommended for the 2020 - 2021 Northern Hemisphere influenza season:
  • A/Brisbane/02/2018 (IVR-190) (an A/Brisbane/02/2018 (H1N1)pdm09 – like virus), A/Kansas/14/2017 (X-327) (an A/Kansas/14/2017 (H3N2) – like virus), B/Maryland/15/2016 (a B/Colorado/06/2017 – like virus) and B/Phuket/3073/2013 BVR-1B (a B/Phuket/3073/2013 – like virus). A 0.25 mL dose contains 7.5 mcg HA of each of the same four influenza strains.